<DOC>
	<DOCNO>NCT00699920</DOCNO>
	<brief_summary>Primary objective demonstrate non-inferiority PCR ( Polymerase Chain Reaction ) adjust adequate clinical parasitological response Day 28 Coarsucam versus Coartem , base first malaria attack patient . Secondary objective : For first attack : To compare 2 group treatment term : - Day 42 efficacy - Parasitological fever clearance - Clinical Biological tolerability - Evolution gametocyte carriage For attack 2nd following : To compare 2 group treatment term : - Day 28 Day 42 clinical parasitological effectiveness - Clinical Biological tolerability - Proportion patient without fever Day 3 - Proportion patient without parasite Day 3 - Evolution gametocyte carriage - Compliance During total follow cohort : To compare 2 group treatment term : - Treatment incidence density - Impact repeat treatment clinical biological tolerability - Impact anaemia - Impact Hackett score .</brief_summary>
	<brief_title>Cohort Study Uganda Comparing Artesunate + Amiodaquine ( Coarsucam ) Versus Artemether + Lumenfantrine ( Coartem ) Treatment Repeated Uncomplicated Plasmodium Falciparum Malaria Attacks</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Falciparum</mesh_term>
	<mesh_term>Lumefantrine</mesh_term>
	<mesh_term>Artemether</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Artemether-lumefantrine combination</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<criteria>Specific inclusion criterion initial enrollment : Confirmed mono infection Plasmodium falciparum , parasite density ≥2000 asexual form per µl blood , Inclusion criterion attack : Body weight ≥5 kg Able treat oral route Fever ( axillary temperatur ≥37.5 degree Celsius ) D0 history fever within previous 24 hour Confirmed Plasmodium falciparum infection positive paratesimia Haemoglobin value ≥5.0 g/dl Specific exclusion criterion initial enrollment : Patient participate another ongoing clinical trial Allergy one investigational medicinal product History hepatic ( ) haematological impairment treatment amodiaquine History cardiac disease Concomitant febrile illness Exclusion criterion attack : Presence least one danger sign malaria : recent history convulsion ( 12 within 24h ) , unconsciousness state , lethargy , unable drink breast feed , vomit everything , unable stand/sit due weakness Severe concomitant disease know disturbance electrolyte balance hypokalaemia hypomagnesaemia Intake medication metabolize cytochrome CYP 2D6 ( e.g . metoprolol , flecainide , imipramine , amitriptyline , clomipramine ) time inclusion Intake drug know inhibit CYP 2A6 ( e.g . methoxsalem , pilocarpine , tranylcypromine ) and/or 2C8 cytochrome ( e.g . trimethoprim , ritonavir , ketoconazole , montelukast , gemfibrozil ) time inclusion Intake medication know prolong QTc interval , class IA III antiarrythmics , neuroleptic , antidepressant agent , certain antibiotic include drug macrolide class , fluoroquinolones , imidazole triazole , antifungal agent , certain nonsedative anthistamines ( terfenadine , astemizole ) cisapride time inclusion Patient receive artesunate + amiodaquine artemether + lumefantrine suitable dosage within previous 2 week . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>59 Months</maximum_age>
	<verification_date>June 2010</verification_date>
</DOC>